Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
Metrics: PDF 1210 views | HTML 1888 views | ?
Chenkui Miao1,*, Jingyi Cao2,*, Yuhao Wang1,*, Bianjiang Liu1 and Zengjun Wang1
1State Key Laboratory of Reproductive Medicine and Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2Department of Urology, Xuzhou Cancer Hospital, Xuzhou, China
*These authors contributed equally to this work
Bianjiang Liu, email: [email protected]
Zengjun Wang, email: [email protected]
Keywords: VEGF/VEGFR, polymorphisms, metastatic renal cell carcinoma, sunitinib, meta-analysis
Received: July 11, 2017 Accepted: July 26, 2017 Published: August 04, 2017
To summarize and clarify the association between vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms and the outcome in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. A total of 8 studies including 900 patients were analyzed in this systematic review after screening the database of PubMed, EMBASE and Web of Science. Hazard ratios (HRs) with 95% confidence interval (CI) were used to evaluate the strength of the association. VEGFR1 rs9582036 AA/AC carriers and rs9554320 CC/AC carriers had more favorable overall survival (OS) in patients with mRCC treated with sunitinib (n = 3), but not in progression-free survival (PFS). In addition, VEGFA rs2010963 was associated with poorer PFS of mRCC (n = 1). VEGFA rs699947 was significant in predicting PFS by univariate analysis, but showed no statistical significance in OS (n = 1). VEGFR2 rs1870377 was verified to be associated with sunitinib OS (n = 1). Furthermore, patients with VEGFR3 rs307826 and rs307821 had shorter PFS and OS during sunitinib therapy (n = 2, respectively). Our results suggested that VEGF and VEGFR polymorphisms were associated with outcomes in sunitinib treated mRCC patients, especially VEGFR1 polymorphisms. However, considering the limited study numbers, its clinical application in sunitinib treated mRCC still needs further confirmation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.